Biomarkers /
MAP2K2
Overview
Mitogen-activated protein kinase kinase 2 (MAP2K2) is a gene that encodes a protein that is a member of the MAP kinase kinase family. The protein functions as a dual specificity protein kinase that regulates mitogen growth factor signal transduction by phosphorylating and activating MAPK1/ERK2 and MAPK2/ERK3. Missense and silent mutations are observed in cancers such as bone cancer, skin cancer, and stomach cancer.
MAP2K2 is altered in 0.86% of all cancers with colon adenocarcinoma, lung adenocarcinoma, cutaneous melanoma, breast invasive ductal carcinoma, and high grade ovarian serous adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in MAP2K2 are MAP2K2 Mutation (0.63%), MAP2K2 Loss (0.15%), MAP2K2 Amplification (0.09%), MAP2K2 R231C (0.03%), and MAP2K2 Fusion (0.02%) [3].
Clinical Trials
Significance of MAP2K2 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.